UK-based Myovant Sciences has rejected a $2.5 billion takeover bid from Sumitovant Biopharma and its parent company Sumitomo Pharma.
Shionogi said that its investigational COVID-19 treatment ensitrelvir fumaric acid has shown promising results in a phase 3 clinical trial.
We use cookies only to remember your preferences and provide better browsing experience. We do not sell user information. Here is our privacy policy.